Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Income Tax Expense
Income taxes recognized for the period, including current and deferred tax.
Benitec Biopharma Inc.NASDAQ: BNTC
Income Tax Expense · Q3 FY2026 · quarter ended Mar 2026
Income tax expense remains negative
Q3 FY2026 income tax expense was $0, compared with $0 a year earlier. Trailing-twelve-month income tax expense was $0.
Context
- Income tax expense increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Tax Expense history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Income Tax Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 0 | — |
| FY2024 | 2024-06-30 | 0 | — |
| FY2023 | 2023-06-30 | 0 | — |
| FY2022 | 2022-06-30 | 0 | — |
| FY2021 | 2021-06-30 | 0 | — |
Income Tax Expense vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's LTM Mar 2026 income tax expense of $0 is the 3rd highest of the 10 companies compared; the peer median is $0.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $609.26K | -83.8% | — | 0.7% | |
| LTM Mar 2026 | $104K | +101.8% | — | 0.3% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | -$75K | -211.9% | — | 4.0% | |
| FY2025 | -$842K | +79.0% | — | 18.1% | |
| LTM Mar 2026 | -$5.28M | — | — | 35.7% | |
| Peer median (excluding BNTC) | $0 | -2.4% | — | 2.4% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 59K | 73K | 75K | 0 | 0 |
| Cost of Revenue | 123K | 9K | 0 | 343K | 0 |
| Gross Profit | (64K) | 64K | 75K | (343K) | (396K) |
| Gross Margin | -108.5% | 87.7% | 100.0% | — | — |
| Research & Development | 7.02M | 11.27M | 12.77M | 15.61M | 18.33M |
| Selling, General & Admin | 6.51M | 6.65M | 6.38M | 6.99M | 23.43M |
| Operating Expenses | 13.53M | 17.92M | 19.16M | 22.49M | 41.77M |
| Depreciation & Amortization | 424K | 392K | 381K | 343K | 396K |
| EBITDA | (13.45M) | (17.78M) | (18.7M) | (22.15M) | (41.37M) |
| EBITDA Margin | -22800.0% | -24361.6% | -24933.3% | — | — |
| Operating Income | (13.6M) | (17.85M) | (19.08M) | (22.49M) | (41.77M) |
| Operating Margin | -23044.1% | -24457.5% | -25441.3% | — | — |
| Interest Income | 0 | 0 | 0 | 904K | 0 |
| Interest Expense | 6K | 32K | 33K | 0 | 0 |
| Other Income / Expenses | (286K) | (354K) | (481K) | 739K | 3.85M |
| Income Before Tax | (13.88M) | (18.21M) | (19.56M) | (21.75M) | (37.92M) |
| Pre-Tax Margin | -23528.8% | -24942.5% | -26082.7% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (13.88M) | (18.21M) | (19.56M) | (21.75M) | (37.92M) |
| Net Margin | -23528.8% | -24942.5% | -26082.7% | — | — |
| EPS (Basic) | (27.27) | (19.31) | (14.12) | (2.68) | (1.05) |
| EPS (Diluted) | (27.27) | (19.31) | (14.12) | (2.68) | (1.05) |
| Weighted Avg Shares | 1.01M | 1.92M | 1.39M | 10.26M | 36.21M |
| Weighted Avg Shares (Diluted) | 1.01M | 1.92M | 1.39M | 10.28M | 36.21M |
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.